trial · primary record
Bortezomib
Chronic Myeloid Leukemia (CML)
| Phase | Phase 1 |
|---|---|
| Status | COMPLETED |
| Sponsor | Unknown |
| Enrolment | 35 |
| Primary completion | 2021-04-06 |
| Primary endpoint | safety of escalating NK cell doses of adoptively infused ex vivo expanded autologous NK cells in subjects with treatment refractory metastatic tumors or hematological malignancies that are sensitized to NK cell toxicity with bortezomib. |
| Registry ID | NCT00720785 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:32:11.262Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT00720785
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.